Product logins

Find logins to all Clarivate products below.


Biosimilars | Market Events and Forecast | Oncology | 2022

In 2020, sales of branded MAb biologics in oncology exceeded $30 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $3 billion. Throughout the 2020-2030 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Biosimilars – Corporate Strategies – Biosimilar Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Biosimilars – Corporate Strategies – Reference Brand Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing…